Asset Details
MbrlCatalogueTitleDetail
Do you wish to reserve the book?
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
by
Noris, Marina
, Remuzzi, Giuseppe
, Donadelli, Roberta
in
Alternative pathway
/ Autoantibodies
/ Autoimmune diseases
/ Complement activation
/ Complement component C3
/ Complement component C3b
/ Complement factor H
/ Complement inhibitors
/ Glomerulonephritis
/ Immunofluorescence
/ Immunoglobulin G
/ Kidney diseases
2019
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
You are currently in the queue to collect this book. You will be notified once it is your turn to collect the book.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
by
Noris, Marina
, Remuzzi, Giuseppe
, Donadelli, Roberta
in
Alternative pathway
/ Autoantibodies
/ Autoimmune diseases
/ Complement activation
/ Complement component C3
/ Complement component C3b
/ Complement factor H
/ Complement inhibitors
/ Glomerulonephritis
/ Immunofluorescence
/ Immunoglobulin G
/ Kidney diseases
2019
Oops! Something went wrong.
While trying to remove the title from your shelf something went wrong :( Kindly try again later!
Do you wish to request the book?
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
by
Noris, Marina
, Remuzzi, Giuseppe
, Donadelli, Roberta
in
Alternative pathway
/ Autoantibodies
/ Autoimmune diseases
/ Complement activation
/ Complement component C3
/ Complement component C3b
/ Complement factor H
/ Complement inhibitors
/ Glomerulonephritis
/ Immunofluorescence
/ Immunoglobulin G
/ Kidney diseases
2019
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
Journal Article
Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy
2019
Request Book From Autostore
and Choose the Collection Method
Overview
Membranoproliferative glomerulonephritis (MPGN) is a rare chronic kidney disease associated with complement activation. Recent immunofluorescence-based classification distinguishes between immune complex (IC)-mediated MPGN, with glomerular IgG and C3 deposits, and C3 glomerulopathies (C3G), with predominant C3 deposits. Genetic and autoimmune abnormalities causing hyperactivation of the complement alternative pathway have been found as frequently in patients with immune complex-associated MPGN (IC-MPGN) as in those with C3G. In the last decade, there have been great advances in research into the autoimmune causes of IC-MPGN and C3G. The complement-activating autoantibodies called C3-nephritic factors (C3NeFs), which are present in 40–80% of patients, form a heterogeneous group of autoantibodies that stabilise the C3 convertase or the C5 convertase of the alternative pathway or both. A few patients, mainly with IC-MPGN, carry autoantibodies directed against the two components of the alternative pathway C3 convertase, factors B and C3b. Finally, autoantibodies against factor H, the main regulator of the alternative pathway, have been reported in a small proportion of patients with IC-MPGN or C3G. The identification of distinct pathogenetic patterns leading to kidney injury and of targets in the complement cascade may pave the way for tailored therapies for IC-MPGN and C3G, with specific complement inhibitors in the development pipeline.
Publisher
Springer Nature B.V
MBRLCatalogueRelatedBooks
Related Items
Related Items
This website uses cookies to ensure you get the best experience on our website.